DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Hemagglutinin 5 (H5) - Pipeline Review, H1 2016" report to their offering.
Hemagglutinin 5 (H5) is a viral protein. It binds to sialic acid-containing receptors on the cell surface. This attachment induces virion internalization through clathrin-dependent endocytosis and through a clathrin- and caveolin-independent pathway. It plays a major role in the determination of host range restriction and virulence.
The Hemagglutinin 5 (H5) pipeline target constitutes close to 9 molecules, out of which approximately 8 molecules are developed by companies and the remaining by universities. The molecules developed by companies in Phase I, Preclinical and Discovery stages are 3, 3 and 2, respectively. Similarly, the universities portfolio in Discovery stages comprises 1 molecule, respectively.
Hemagglutinin 5 - Pipeline Review, H1 2016, outlays comprehensive information on the Hemagglutinin 5 (H5) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Hemagglutinin 5 (H5) targeted therapeutics development and features dormant and discontinued projects and the latest news and press releases.
Key Topics Covered:
- Introduction
- Hemagglutinin 5 Overview
- Therapeutics Development
- Pipeline Products for Hemagglutinin 5 - Overview
- Pipeline Products for Hemagglutinin 5 - Comparative Analysis
- Hemagglutinin 5 - Therapeutics under Development by Companies
- Hemagglutinin 5 - Therapeutics under Investigation by Universities/Institutes
- Hemagglutinin 5 Products Glance
- Late-Stage Products
- Clinical-Stage Products
- Early-Stage Products
- Hemagglutinin 5 - Products under Development by Companies
- Hemagglutinin 5 - Products under Investigation by Universities/Institutes
- Hemagglutinin 5 - Companies Involved in Therapeutics Development
- Altravax, Inc.
- Ilyang Pharmaceutical Co., Ltd.
- Inovio Pharmaceuticals, Inc.
- NewLink Genetics Corporation
- Vaxine Pty. Ltd.
For more information about this report visit http://www.researchandmarkets.com/research/9w3gpg/hemagglutinin_5.
Related Topics: Infectious Diseases Drugs
